Pliant Therapeutics, Inc. is a biopharmaceutical company in the clinical development stage, dedicated to discovering, advancing, and bringing to market innovative therapies for fibrotic and related diseases across the United States. Its flagship investigational product, PLN-74809, is an orally administered, small-molecule, dual-selective inhibitor targeting both avß6 and avß1 integrins, which is currently progressing through three distinct Phase 2a clinical trials. The company's pipeline also includes PLN-1474, a small-molecule selective inhibitor of avß1, which has successfully completed its Phase 1 clinical assessment for treating liver fibrosis associated with nonalcoholic steatohepatitis (NASH). Furthermore, Pliant is nurturing two additional integrin-based initiatives in preclinical development: one focused on oncology, and another involving an allosteric agonistic monoclonal antibody designed to act upon an undisclosed integrin receptor for the treatment of various muscular dystrophies, including Duchenne muscular dystrophy. Founded in 2015, Pliant Therapeutics, Inc. maintains its corporate headquarters in South San Francisco, California.
seekingalpha.comPliant Therapeutics, Inc. (PLRX) Presents at RBC Capital Markets Global Healthcare Conference 2026 Transcriptseekingalpha.comMay 22
globenewswire.comPliant Therapeutics Announces Upcoming Presentation at the 2026 American Society of Clinical Oncology Annual Meetingglobenewswire.comMay 21
globenewswire.comPliant Therapeutics Provides Corporate Update and Reports First Quarter 2026 Financial Resultsglobenewswire.comMay 11
globenewswire.comPliant Therapeutics to Participate in the RBC Capital Markets Global Healthcare Conferenceglobenewswire.comMay 6
globenewswire.comPliant Therapeutics Announces First Patient Dosed in FORTIFY, the Phase 1b Indication Expansion Trial Evaluating PLN-101095 in Patients with ICI-Refractory Solid Tumorsglobenewswire.comApr 30